News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2024-03-21 11:24:37 am MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript SeekingAlpha
2024-03-21 4:0:0 am MiNK Reports Fourth Quarter and Year-End 2023 Results GlobeNewswire
2024-03-07 4:30:0 am MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report GlobeNewswire
2024-03-06 5:30:0 am MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 GlobeNewswire
2024-02-14 5:0:0 am First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab GlobeNewswire
2024-02-06 5:0:0 am MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications GlobeNewswire
2024-01-30 5:0:0 am MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene GlobeNewswire
   

Please consider a small donation if you think this website provides you with relevant information